EU Commission authorises medicine for treatment of Alzheimer’s disease early stages

Brussels – The European Commission has granted marketing authorisation in the EU for Kisunla, a medicine for the treatment of mild cognitive impairment, including mild dementia in the early stages of Alzheimer’s disease. 

Kisunla may help slow the progression of cognitive and functional issues associated with Alzheimer’s disease in some patients. The authorisation is based on positive scientific assessment by the European Medicines Agency, which concluded that the benefits of this medicine outweigh the risks for a specific population of patients with early-stage Alzheimer’s disease. 

The authorisation decision lays down strict conditions for the use of Kisunla, as it is only deemed suitable for patients with a particular genetic disposition. Clear risk mitigation measures, such as monitoring and labelling requirements, are also outlined.